It potently reduces intracellular KYN levels and IDO1-induced T cell anergy, and slows tumor cell growth, both in-vitro and in-vivo, in monotherapy and combined with antibodies directed against PD-L1 [131]. The gene discussed is IDO1; the disease is neoplasm.